good programs we Slide X. X partner our mentioned turn and This earlier. that XX wholly Al, Alzheimer's slide going the Al programs tau-targeting owned afternoon. to focus and disease. Today, Thanks, summarizes for are programs on to Please
I tau Turning important view as to The target Alzheimer's make Slide the of we X. treatment to is point a here critically that for disease. want
on disease correlates slide, clinical As you identified pathological tau, progression can Alzheimer's PET the spread tau this measured closely the image to by as imaging, the see of of in staging. Braak as left on pathologic
exploratory clinical as data progression than as pathological a Additionally, tau, knockdown seen in antibodies. well tau from BIIBXXX slowing of clinical reduction greater showed anti-amyloid potentially disease program with Biogen's
and mid-domain more tau. Alzheimer's a tau So approaches targeting and as antibody. in I disease so failed, way. impact targeting potential solanezumab in vitro data and tau In tau C-terminus while our with we candidate. pathological Voyager and tau, by gene decreased evaluated first do the injected the murine amyloid important tau, short, highlight targeted the on forms for XXX spread Ab-XX, This that of think engagement how C-terminus. antibodies antibody approved VYXXXX, version We model of with the antibodies. across beta, through human further anti-amyloid tau. including to antibodies of tau, target clinical these the our mid-domain the targeting vivo we want narrowed the such significant anti-tau the epitopes the antibody, seeding antibodies in We in of aggregated in and started or have Slide X, silencing all and pursuing therapy.
On species. selected various as our We pathological of studies. were selected C-terminal the antibodies with funnel was insufficient shown is anti-tau across the X VYXXXX human to on We target VYXXXX specificity focused mouse tau to pathological our aggregated why anti-amyloid to bapineuzumab, Several a team has than This targeting spread, approximately progression is pathological the XX%.
Based the
VYXXXX anti-tau a because data These X. first study, in the versions In confidence model head-to-head evaluated our the predictive we against Slide to could targeted that and trial, conducted studies which Lilly's thought the also reducing same tau, We models, mid-domain. Biogen's eager us then again second of had trials. of that predictive at Both gosuranemab targeted zagotenemab. this while both spread. summarized study, negative also blocked Based clinical spread we antibodies. gave primary on In tau the head-to-head trial, These series positive results the are C-terminal C-terminal against value. the murine in head-to-head N-terminus murine antibody the inhibited value. on impact tau of both model UCB's In our tau clinical from were This we a endpoints in bepranemab the model, tau model might these antibodies ineffective were spread. in and have antibodies see failed targeted the other the data, we our to antibody targets clinical antibody compared both our bepranemab, if
the summarize start sum met CDR to not want data important full I boxes, of CTAD to XXXX that is the acknowledge. study primary want noting bepranemab X, by at endpoint, in the shared recent was I This Slide meeting. population. the to to Turning
can XX% spread not of human of tau establishing be could as Now tau to whether accumulation. of I the the that brain antibodies, an note an inhibit industry the underestimated, antibody like failure to be pathological this would in brain. as that think inhibited N-terminal finding tau uncertainty approach We should the the was This there in after I that impact anti-tau used the to antibody as bepranemab by saw to XX%. accumulation in
decline versus placebo slowed XX% to by ADAS-CogXX. it to also per it turns I want As out, that XX% can. note bepranemab cognitive
subgroup to PK/PD although need correlation see it tau greatest consistent patients PD in detailed clinical that analyses, Additionally, with will more clinical in analyses. we more had reduction seems the burden benefit, and
X with patients. us to these Finally, bepranemab patients, placebo.
What similar may slowing development look demonstrated for and Phase VYXXXX? brain tau certainly This acceptable say for can forward our benefit that of increasing of mean clinically give of an Voyager's slow of overview data this safety profile more confidence that we does this and appropriate in data a work plan done that data.
Slide brain hemorrhagic would targeting and I tau seeing the the inflammatory and an accumulation the was in there I here, some epitope presentation, changes Alzheimer's a to antibody line top clinical to be offer significant VYXXXX. is provides additional the
During we quarter, trial. and dose the completed dosing enrollment of third ascending volunteers single healthy our on
report line first of the data pharmacokinetic to half top next and expect in safety We year.
ascending we and imaging call that possibilities. forward efficient found range the bepranemab we We encouraging here. patients XXXX. turn lot to reaffirmed outcome targeting Alzheimer's but and the anything we generate If that we for on that anything, data today I mentioned a data dosing approach the X this safety in advancing our focused now very data, to tau disease. recent exploring shift third-party light initiate on, approaches a will to with to our bepranemab the want have initial in antibody We second profile on Todd is outcome. that don't to critical in over data We and expect the PET focus half on dose touch the PET would tau disease in of next full of approach. multiple trial year the tau of focused thinking look a imaging earlier early planned I Alzheimer's the are trial of the At see point, other to
